RXi Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch RXII and buy or sell other stocks, ETFs, and their options commission-free!

About RXII

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. 

CEO
Angelos M. Stergiou, MD
CEOAngelos M. Stergiou, MD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2006
Founded2006
Employees
Employees

RXII Key Statistics

Market cap
848.95M
Market cap848.95M
Price-Earnings ratio
-20.77
Price-Earnings ratio-20.77
Dividend yield
Dividend yield
Average volume
7.88M
Average volume7.88M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$6.14
52 Week high$6.14
52 Week low
$0.9516
52 Week low$0.9516

Stock Snapshot

With a market cap of 848.95M, RXi Pharmaceuticals(RXII) trades at $2.32. The stock has a price-to-earnings ratio of -20.77.

RXi Pharmaceuticals(RXII) stock opened on 2026-03-10 at —. The price climbed to — and dipped to —.

RXi Pharmaceuticals(RXII) shares are trading with a volume of 0, against a daily average of 7.88M.

In the last year, RXi Pharmaceuticals(RXII) shares hit a 52-week high of $6.14 and a 52-week low of $0.95.

In the last year, RXi Pharmaceuticals(RXII) shares hit a 52-week high of $6.14 and a 52-week low of $0.95.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.